For Sirna, Talks on Drug-Development Deal Turn Into $1.1B Bet by Merck

“We had no intention of selling the company,” according to a Sirna official. But in the end the price offered by Merck, which has been one of the first drug giants to place big bets in RNAi, proved too good to pass up.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.